StockData
Sinovac Biotech Ltd logo

Sinovac Biotech Ltd (SVA) stock

SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026Score 7/30
$6.47+0.00 (0.00%)

Close on Nov 19, 2026Market cap $464.94MP/E –Yield 850.08%

Sinovac Biotech gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2025 it was $261.98M, up 18.7% from the year before. Over ten years it grew 18.3% a year on average. The highest annual figure on record is $18.38B in fiscal 2021.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$261.98M+18.7%
FY2024Dec 31, 2024$220.69M-31.7%
FY2023Dec 31, 2023$323.32M-60.3%
FY2022Dec 31, 2022$815.24M-95.6%
FY2021Dec 31, 2021$18.38B+4044.0%
FY2020Dec 31, 2020$443.44M+107.6%
FY2019Dec 31, 2019$213.58M+4.2%
FY2018Dec 31, 2018$204.93M+33.0%
FY2017Dec 31, 2017$154.11M+208.0%
FY2016Dec 31, 2016$50.04M+2.1%
FY2015Dec 31, 2015$49.01M+3.3%
FY2014Dec 31, 2014$47.46M-7.4%
FY2013Dec 31, 2013$51.27M+70.2%
FY2012Dec 31, 2012$30.12M-15.7%
FY2011Dec 31, 2011$35.71M+114.1%
FY2010Dec 31, 2010$16.68M-74.0%
FY2009Dec 31, 2009$64.13M–

More Sinovac Biotech figures

See a number that looks wrong?